Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] hepatone dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX

G. Tagliabue, S. Filippeschi, H. Hendricks, M. D'Incalci

Research output: Contribution to journalArticle

Abstract

We investigated the antitumoral activity of Dabis Maleate given on different dosage schedules and as continuous infusion in a murine reticular cell sarcoma M5076 (M5) and in a subline made resistant to cyclophosphamide and other nitrogen mustards (M5/CTX). The therapeutic index of Dabis Maleate was clearly better when the drug was given as a continuous 72-h infusion. Dabis Maleate appeared non-cross-resistant to cyclophosphamide and this property renders it interesting for further clinical development.

Original languageEnglish
Pages (from-to)233-236
Number of pages4
JournalAnnals of Oncology
Volume3
Issue number3
Publication statusPublished - 1992

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Cite this